136 related articles for article (PubMed ID: 23561850)
1. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
3. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes.
Garbe Y; Maletzki C; Linnebacher M
PLoS One; 2011; 6(11):e26517. PubMed ID: 22110587
[TBL] [Abstract][Full Text] [Related]
4. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
5. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
7. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
9. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.
Linnebacher M; Gebert J; Rudy W; Woerner S; Yuan YP; Bork P; von Knebel Doeberitz M
Int J Cancer; 2001 Jul; 93(1):6-11. PubMed ID: 11391614
[TBL] [Abstract][Full Text] [Related]
10. Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability.
Kim CJ; Lee JH; Song JW; Cho YG; Kim SY; Nam SW; Yoo NJ; Park WS; Lee JY
Eur J Surg Oncol; 2007 Jun; 33(5):580-5. PubMed ID: 17408908
[TBL] [Abstract][Full Text] [Related]
11. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
[TBL] [Abstract][Full Text] [Related]
12. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
13. A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors.
Agostini M; Enzo MV; Morandi L; Bedin C; Pizzini S; Mason S; Bertorelle R; Urso E; Mescoli C; Lise M; Pucciarelli S; Nitti D
Cancer Biomark; 2010; 6(1):49-61. PubMed ID: 20164541
[TBL] [Abstract][Full Text] [Related]
14. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
Bauer K; Nelius N; Reuschenbach M; Koch M; Weitz J; Steinert G; Kopitz J; Beckhove P; Tariverdian M; von Knebel Doeberitz M; Kloor M
Cancer Immunol Immunother; 2013 Jan; 62(1):27-37. PubMed ID: 22729559
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability.
Ishikawa T; Fujita T; Suzuki Y; Okabe S; Yuasa Y; Iwai T; Kawakami Y
Cancer Res; 2003 Sep; 63(17):5564-72. PubMed ID: 14500396
[TBL] [Abstract][Full Text] [Related]
16. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.
Borie C; Colas C; Dartigues P; Lazure T; Rince P; Buhard O; Folliot P; Chalastanis A; Muleris M; Hamelin R; Mercier D; Oliveira C; Seruca R; Chadburn A; Leblond V; Barete S; Gaïdano G; Martin A; Gaulard P; Fléjou JF; Raphael M; Duval A
Int J Cancer; 2009 Nov; 125(10):2360-6. PubMed ID: 19551857
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia.
Nomdedéu JF; Perea G; Estivill C; Lasa A; Carnicer MJ; Brunet S; Aventín A; Sierra J
Ann Hematol; 2005 Jun; 84(6):368-75. PubMed ID: 15789228
[TBL] [Abstract][Full Text] [Related]
18. Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO).
Linnebacher M; Wienck A; Boeck I; Klar E
J Biomed Biotechnol; 2010; 2010():841451. PubMed ID: 20339516
[TBL] [Abstract][Full Text] [Related]
19. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes.
Wu MS; Lee CW; Shun CT; Wang HP; Lee WJ; Chang MC; Sheu JC; Lin JT
Genes Chromosomes Cancer; 2000 Apr; 27(4):403-11. PubMed ID: 10719371
[TBL] [Abstract][Full Text] [Related]
20. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.
Saeterdal I; Gjertsen MK; Straten P; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2001 Nov; 50(9):469-76. PubMed ID: 11761441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
